Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis
Author:
Affiliation:
1. Astellas Pharma, Inc.; Northbrook Illinois, USA
2. K Papp Clinical Research and Probity Medical Research; Waterloo Canada
3. Astellas Pharma, Inc.; Tokyo Japan
4. Auckland Clinical Studies Ltd; Auckland New Zealand
Funder
Astellas Pharma, Inc. under the co-development partnership with Kyowa Hakko Kirin Co.
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine
Reference26 articles.
1. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases;Albach;European Journal of Clinical Pharmacology,2018
2. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy;Aoyagi;American Journal of Transplantation,2009
3. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma;Bensinger;British Journal of Haematology,2012
4. New insights of T cells in the pathogenesis of psoriasis;Cai;Cellular & Molecular Immunology,2012
5. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey;Kerkhof;Journal of European Academy of Dermatology and Venereology,2015
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Differential induction of donor-reactive Foxp3+ regulatory T cell via blockade of CD154 vs CD40;American Journal of Transplantation;2024-08
2. Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab;Biochemical and Biophysical Research Communications;2024-06
3. Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis;JACC: Basic to Translational Science;2024-06
4. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?;Clinical and Experimental Immunology;2024-04-20
5. New molecular targets in the treatment of rheumatoid arthritis;Current Opinion in Rheumatology;2024-01-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3